Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial - Scorecard - MDSpire
Advertisement
Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial
Clinical Scorecard: Swift Therapeutic Effects and Enhanced Quality of Life in Chinese Individuals with Plaque Psoriasis Following Treatment with Calcipotriol and Betamethasone Dipropionate Aerosol Foam: Results from a Randomized Phase 3 Study
At a Glance
Category
Detail
Condition
Plaque Psoriasis
Key Mechanisms
Topical treatment using Calcipotriol and Betamethasone Dipropionate in aerosol foam formulation.
Target Population
Native Chinese adults aged ≥ 18 years with stable plaque psoriasis.
Care Setting
Multi-center clinical trial across 39 medical research centers and hospitals in China.
Key Highlights
Cal/BD foam demonstrated rapid onset of action and improved quality of life.
Efficacy outcomes were comparable or superior to Cal/BD ointment.
Treatment adherence is likely to improve with rapid symptom relief.
Safety profile of Cal/BD foam was similar to that of Cal/BD ointment.
Majority of adverse events were mild and not treatment-related.
Guideline-Based Recommendations
Diagnosis
Clinical diagnosis of stable plaque psoriasis with specific severity criteria.
Management
Use of Cal/BD foam once daily for 4 weeks as a treatment option.
Monitoring & Follow-up
Assess efficacy using the Physician’s Global Assessment and modified Psoriasis Area and Severity Index.
Risks
Monitor for mild adverse events; no new safety concerns identified.
Patient & Prescribing Data
Native Chinese adults with mild to moderate plaque psoriasis affecting 2-30% of body surface area.
Cal/BD foam is a promising alternative to standard Cal/BD ointment.
Clinical Best Practices
Encourage treatment adherence through rapid symptom relief.
Utilize patient-reported outcomes to assess quality of life improvements.
Conduct regular monitoring of treatment efficacy and safety.
by Lin Cai, Furen Zhang, Guoqiang Zhang, Yangfeng Ding, Yan Zhou, Shanshan Li, Juan Tao, Wei Yan, Rong Xiao, Bin Yang, Jianjun Qiao, Xiaoyong Man, Zaixing Wang, Adam El Mongy Jørgensen, Merle Kurvits, Jens Strodl Andersen, Jianzhong Zhang
